Karyopharm’s Mission

Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer.

We seek to foster scientific creativity with pioneering technologies and developmental approaches within an innovative culture that will accelerate first-in-class small molecule modulators of nuclear transport into effective therapeutics for life-threatening conditions.

At Karyopharm, we support a culture of innovation, courage, urgency, resiliency and energy with our employees and collaborators. Integrity and respect are core to our success.
Karyopharm at a Glance

• Fully integrated, commercial-stage, global oncology company
• Novel technology approach with potential for broad clinical applicability
  ➢ Industry leader in targeting nuclear export dysregulation as a mechanism to treat cancer
• First drug, XPOVIO® (selinexor), received accelerated approval from the FDA in July 2019
  ➢ Successful commercial launch with strong patient and physician demand
• Pivotal Phase 3 BOSTON study top-line data announced on March 2, 2020; Study met primary endpoint of a statistically significant increase in progression-free survival (PFS)
• MAA submitted for Europe in January 2019 with decision expected in late-2020
• sNDA in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) accepted by FDA with Priority Review granted and PDUFA date set for June 23, 2020
• Recently initiated randomized, global clinical study to evaluate low dose oral selinexor in patients with severe COVID-19
• Ongoing clinical development for selinexor and next-generation programs in earlier lines of treatment, in combination trials, and in additional tumor types across both hematologic and solid tumor malignancies
• All programs developed in-house with patent protection on lead compound to 2032+
• Numerous data read-outs and potential key milestones expected over the next 12-24 months
Speakers

Pierre S. Sayad, PhD, MS
Vice President, Global Medical and Scientific Affairs

Dr. Sayad joined Karyopharm in 2018 and is responsible for overseeing the company’s Medical Affairs organization, including Scientific Communication, Medical Information, and the U.S. and European Medical Science Liaisons (MSLs) teams.

Dr. Sayad began his career at Eli Lilly and Company within the commercial organization and helped drive the successful launches of the neuroscience blockbusters Zyprexa®, Cymbalta®, and Strattera®. He then joined the strategic management consulting firm Campbell Alliance and worked across multiple practice areas, with a strong focus in Medical Affairs, and led engagements for numerous biotech clients. Joining Onyx Pharmaceuticals in 2011, Dr. Sayad led the Medical Strategy and Operations team and supported the scientific development and subsequent approval and launch of Kyprolis® for relapsed refractory multiple myeloma. Just prior to joining Karyopharm, Dr. Sayad led the global medical affairs and business development organizations at the International Myeloma Foundation (IMF) as SVP, Global Medical Affairs and Strategic Partnerships.

Dr. Sayad earned his undergraduate degrees from San Jose State University and holds Bachelor of Science degrees in Molecular Physiology and Psychology, and a Bachelor of Arts in Music. He completed his graduate work at the School of Medicine, Loma Linda University achieving Master of Science degrees in Molecular Physiology and BioMedical Sciences. Dr. Sayad completed his graduate work in the field of multiple myeloma and holds a Doctor of Philosophy in Psychoneuroimmunology (PNI).
Yosef Landesman, PhD
Senior Vice President, Research and Translational Medicine

Dr. Landesman joined Karyopharm in 2011, where he began as Director, Head of Biology and currently serves as the Senior Vice President of Research and Translational Medicine. In this role, he leads Preclinical and Clinical Research, Karyopharm’s Expanded Access Program, as well as the departments of Translational Development, Preclinical Pharmacology, Bioinformatics, and Clinical and Preclinical Publications. During his time at Karyopharm, Dr. Landesman has expanded on his broad experience in oncology at virtually every stage of drug development: from early discovery through clinical trial and approval. He led the preclinical development of XPOVIO® (selinexor) and initiated discovery of the Pak4/NAMPT dual inhibitor KPT-9274, currently in a Phase 1 clinical trial.

Prior to joining Karyopharm, Dr. Landesman worked at Alnylam Pharmaceuticals where he had a critical role in the establishment of the “RNAi Lead Development” department. In this multi-faceted position, he developed and optimized an efficient and simple method to quantify the delivery of siRNA and significantly contributed to the development of ONPATTRO® (patisiran). In addition, he was instrumental in a technology transfer agreement between Alnylam and Takeda Pharmaceuticals. He began his career as a scientist at GPC Biotech where he developed CDK small drug inhibitors and had a leadership role in the collaboration between GPC Biotech and the ALTANA Research Institute.

Dr. Landesman received his Bachelor and Master of Science degrees in Genetics from the Hebrew University of Jerusalem. He went on to earn his Doctor of Philosophy in Molecular Genetics and Virology from the Weizmann Institute of Science and completed his postdoctoral training at Harvard Medical School where he was also a faculty member of the Neurology Department.
Speakers

Hongwei Wang, MD/PhD
Vice President, Clinical Development

Dr. Hongwei Wang joined Karyopharm in 2019 as the Vice President of Clinical Development and is responsible for the planning and execution of Karyopharm’s clinical programs.

Dr. Wang is a senior drug development expert and has over 10 years of experience in Oncology clinical development in industry, and over 20 years of experience in cancer research. Dr. Wang’s career in industry began in 2006 and she has worked at several pharmaceutical companies including Novartis and Cerulean Pharma. Just prior to joining Karyopharm Dr. Wang was at Curis, Inc. where she served as the company’s Executive Medical Director.

Dr. Wang received her MD/PhD from Peking Union Medical College in Beijing, China.